Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $260 | $228 | $209 | $166 |
| % Growth | 13.9% | 9.1% | 26.1% | – |
| Cost of Goods Sold | $165 | $147 | $136 | $95 |
| Gross Profit | $95 | $81 | $73 | $70 |
| % Margin | 36.5% | 35.7% | 34.8% | 42.4% |
| R&D Expenses | $0 | $13 | $15 | $11 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $71 | $50 | $52 | $40 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$1 |
| Operating Expenses | $71 | $64 | $67 | $51 |
| Operating Income | $23 | $18 | $6 | $19 |
| % Margin | 9% | 7.7% | 2.6% | 11.6% |
| Other Income/Exp. Net | $3 | $7 | -$1 | $3 |
| Pre-Tax Income | $26 | $24 | $5 | $22 |
| Tax Expense | $7 | $8 | $2 | $6 |
| Net Income | $19 | $16 | $2 | $16 |
| % Margin | 7.3% | 7.1% | 1.1% | 9.6% |
| EPS | 385.71 | 328.59 | 44.72 | 323.35 |
| % Growth | 17.4% | 634.8% | -86.2% | – |
| EPS Diluted | 385.71 | 328.59 | 44.72 | 316.19 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $1 | $1 | $0 |
| Depreciation & Amortization | $20 | $18 | $19 | $11 |
| EBITDA | $48 | $43 | $25 | $29 |
| % Margin | 18.5% | 19% | 11.9% | 17.8% |